Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), announced that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. (NASDAQ: VTRS). Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators, including the U.S. Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors.
Read the full article: Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business //
Source: https://www.prnewswire.com/news-releases/biocon-biologics-completes-acquisition-of-viatris-global-biosimilars-business-301688945.html